Global Rapid Diagnostic Tests Market is poised to see a decent growth of 4.5% from 2021 to 2026

Rapid diagnostic tests or RDTs are simple-to-use procedures that provide results in less than 20 minutes. Unlike most standard diagnostic tests, which are required to be sent to a lab for analysis, RDTs are done and results are provided at the point-of-care. Rapid tests are most frequently used to diagnose infectious diseases, such as flu, malaria, HIV, and COVID 19, among others.

Impact of COVID-19 Pandemic on the Rapid Diagnostic Tests Market

The global rapid diagnostic tests market has experienced a significant impact due to the COVID 19 pandemic. Although the demand for RDTs specifically for the detection of SARS-CoV-2 during 2020 and 2021 increased exponentially, the pandemic showed a negative impact on the sales of RDTs for cancer screening, blood glucose, cardiac markers, and other infectious diseases, among others. However, there has been a significant development in the rapid diagnostic tests market during the last two years; some of these are listed below:

  • In October 2021, the NIH Rapid Acceleration of Diagnostics (RADx) initiative has awarded contracts totalling $77.7 million for the development and manufacturing of 12 new rapid diagnostic tests for SARS-CoV-2; offering high performance and low-cost home and POC tests.
  • In September 2021, LumiraDx, a next-generation POC diagnostics company, launched its LumiraDx SARS-CoV-2 Ag Surveillance Test in the US market, specifically for use at schools and workplaces; which allows simultaneous testing of up to five samples on a small and portable instrument, costing $4 per sample and delivering digital results within 12 minutes.

Collaborations and Acquisitions to boost Adoption and Co-develop Advanced Market Solutions

The rapid diagnostic tests market has witnessed a number of acquisitions by leading market players to either enhance the adoption of these tests or to co-develop advanced diagnostic tests. Some of the strategic initiatives that boost the adoption of RDTs are listed below:

  • In April 2022, bioMérieux entered into an agreement to acquire Specific Diagnostics, a developer of rapid antimicrobial susceptibility test (AST) system. Rapid AST provides fast and accurate AST results while reducing the global antimicrobial resistance (AMR) burden caused by antibiotic resistant pathogens.
  • In February 2022, Sorrento Therapeutics, Inc. acquired a majority ownership of Zhengzhou Fortune Bioscience Co., Ltd. (FortuneBio), a diagnostic product manufacturer and Sorrento’s exclusive OEM manufacturer for COVISTIX. With enhanced sensitivity in detecting the Omicron variant, COVISTIX is a rapid antigen detection test for SARS-CoV-2 and its major variants of concern (VOCs).

Competitive Landscape Analysis: Rapid Diagnostic Tests Market

The global rapid diagnostic tests market is marked by the presence of top market players such as Abbott Laboratories (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Becton, Dickinson and Company (US), and ACON Laboratories, Inc. (US), and others.

Get Customized Report on Rapid Diagnostic Tests Market @ https://meditechinsights.com/rapid-diagnostic-tests-rdts-market/

Comments

Post a Comment

Popular posts from this blog

Global HPV Testing and PAP Test Market is slated to grow at a lucrative CAGR of 12 to 15 % by 2027 – Growing Revolution for the Prevention of Cervical Cancer

Cervical cancer is a malignant tumor which starts in the cells of the cervix, the lowermost part of the uterus. Cervical cancer begins when the cells on its surface transforms into precancerous cells. If not destroyed, these abnormal cells may turn into harmful cancer cells and spread in the cervix and surrounding areas. Cervical cancer screening involves HPV and PAP tests , which can identify HPV infection or pre-cancerous lesions at an early stage and if correct treatment is offered at the right time then the cancer can be prevented. Impact of  Covid-19 on  the Global HPV Testing and PAP Test Market Covid-19 pandemic had impacted the healthcare market in many ways. During Covid pandemic, due to strict social-distancing norms in hospitals, there was a delay in many diagnostic examinations and procedures. The delay in the cancer screening services due to the lack of skilled healthcare staff and disruption in the supply chain of testing kits across the world had led to a severe impact o
Read more

Global Medical Display Market is projected to witness a CAGR of 5% by 2027 - Transforming Medical Imaging

Medical displays are purpose-built solutions which offer quick improvements in viewing angle, longevity, luminance, and noise reduction to assure substantially superior accuracy and effectiveness of medical images. Technological Developments and Innovations in Medical Display Drives the Growth of the Global Medical Display Market With the rapid innovations and developments in medical technology, many high-end medical equipment's are being introduced in the global market. Flat-panel displays, holograms, and head-mounted displays are quickly changing the manner in which medical messages are being communicated. The majority of displays used for medical imaging are liquid crystal displays (LCDs) backlit with either CCFLs or LEDs.  For instance,  In January 2023, Barco announced the release of a new LED solution which completes its next-generation LED portfolio. Adoption of Multimodality Display Fuels the Global Growth of the Medical Display Market  With the fast evolution of the medi
Read more

Global Flow Cytometry Market is estimated to grow at a lucrative rate of 8% to reach $11billion by 2026

Flow Cytometry is a technique used to detect and measure physical and chemical characteristics of a population of cells or particles usually suspended in a fluid using a laser beam. Most common types of flow cytometry-based proliferation assays are cell-based and bead-based  assays. Increasing Adoption of Flow Cytometry Market in Stem Cell Research Flow cytometry and cell sorting are critical tools in stem cell research. Recent advances in flow cytometric hardware, reagents, software platforms and algorithms have synergized to permit the stem cell biologist in better identifying and isolating rare cells based on their immunofluorescence and light scattering characteristics. By multiple fluorescent-labeled antibodies, researchers can obtain robust data and population-based statistics on differentiating stem cell cultures. The growing market penetration in stem cell research, adoption of recombinant DNA technology for antibody production, and evolution of tandem flow cytometry techno
Read more